British technology firm appointed to the global ‘AI 100’ for advancing artificial intelligence in drug discovery

BenevolentAI, a leading British artificial intelligence (“AI”) company today announced it has been appointed by CB Insights to the prestigious Artificial Intelligence 100 list (“AI 100”), a select group of emerging private companies from around the world that are working on ground breaking artificial intelligence technology.


Ken Mulvany, co-founder and Chairman of BenevolentAI commented:

“We are delighted to be recognised as one of the world’s 100 most innovative and important AI companies.  In 2016 we made some landmark senior management hires and demonstrated compelling drug development traction, strong technology progress and major commercial development. We expect 2017 to be another year of clear progress which will see the start of Phase II clinical trials and the continued expansion of our business”

The CB Insights research team selected the AI 100 winners based on a combination of data submitted by the companies, responses to interview questions and the company’s Mosaic Score.  Mosaic is an algorithm built with funding from the National Science Foundation that gives predictive intelligence into the health of private companies.

Anand Sanwal, CEO of CB Insights said:

“From financial services to healthcare to transport, incumbent companies in every industry are seeing that AI will reshape their industries. And as so often happens, transformational innovation comes from emerging companies. In the case of AI, a lot of the ground-breaking work is being done by the AI 100. The companies in the AI 100 are accelerating research, improving efficiency, and making many game-changing advancements that will be felt for decades to come”.


 

Quick facts on the AI 100:

BenevolentAI ($1.7B) is one of five AI 100 companies that have reached a valuation of $1B or more (also known as ‘unicorn’ status). In total, these 100 emerging private companies have raised $3.8B across 263 deals since 2012, according to CB Insights. Applications of their technology include breakthroughs in healthcare, drug discovery, business intelligence, gaming, manufacturing, and much more. More than 1,650 companies were nominated or applied for the AI 100 (only 6% were selected). Data Collective has backed 14 of the AI 100 companies, while NEA backed 8 and Bloomberg Beta backed 7. There have been 9 mega-rounds (funding rounds of $100M or more) to AI 100 companies since 2014. 11 countries are represented among the winners.


FURTHER INFORMATION

Contact press@benevolent.ai 

 

BenevolentAI appointed AI 100 for advancing AI in drug discovery and development